International audienceInjection of the antimitotic drug methylazoxymethanol (MAM) in the pregnant rat at E14 leads in the offsprings to a severe malformation with microcephaly and cortical heterotopiae in the white matter and in the CA1 field of the hippocampus. These animals suffer cognitive and epileptic disorders. Since these pathologies have been associated with glutamatergic transmission abnormalities, we have examined by in situ hybridization and immunohistochemistry the distribution and expression levels of several glutamate receptors subunits in these rats. Examination of the GluR2 flip and flop, NR1, NR2A and NR2B subunit gene transcripts showed a qualitatively similar distribution in both the neocortex and hippocampus of MAM and c...
Methylazoxymethanol acetate (MAM Ac) injected into pregnant rats at a dose of 25 mg/kg at gestationa...
We have generated an experimental ‘double-hit ’ model of chronic epilepsy to recapitulate the co-exi...
Administration of the DNA-alkylating agent methylazoxymethanol acetate (MAM) on embryonic day 17 (E1...
International audienceInjection of the antimitotic drug methylazoxymethanol (MAM) in the pregnant ra...
A double methylazoxymethanol (MAM) intraperitoneal injection was prenatally administered to pregnant...
Double intraperitoneal injections of methylazoxymethanol (MAM) in pregnant rats induce developmental...
International audienceMigration disorders cause neurons to differentiate in an abnormal heterotopic ...
We are currently investigating various treatments which could determine, in the rat brain, structura...
International audienceNeuronal migration disorders have been involved in various pathologies, includ...
We have previously demonstrated that the antiproliferative agent methylazoxymethanol acetate (MAM) i...
International audienceIn humans, cortical malformations are highly epileptogenic. In rats, prenatal ...
The administration of the antimitotic compound methylazoxymethanol (MAM) to gestating rats induces a...
The administration of methylazoxymethanol (MAM) to pregnant rats induced a marked reduction in the w...
Metabotropic glutamate receptors (mGluRs) have been implicated in a number of hippocampal functions ...
Malformations of neocortical development such as microgyria (MG) and periventricular nodular heterot...
Methylazoxymethanol acetate (MAM Ac) injected into pregnant rats at a dose of 25 mg/kg at gestationa...
We have generated an experimental ‘double-hit ’ model of chronic epilepsy to recapitulate the co-exi...
Administration of the DNA-alkylating agent methylazoxymethanol acetate (MAM) on embryonic day 17 (E1...
International audienceInjection of the antimitotic drug methylazoxymethanol (MAM) in the pregnant ra...
A double methylazoxymethanol (MAM) intraperitoneal injection was prenatally administered to pregnant...
Double intraperitoneal injections of methylazoxymethanol (MAM) in pregnant rats induce developmental...
International audienceMigration disorders cause neurons to differentiate in an abnormal heterotopic ...
We are currently investigating various treatments which could determine, in the rat brain, structura...
International audienceNeuronal migration disorders have been involved in various pathologies, includ...
We have previously demonstrated that the antiproliferative agent methylazoxymethanol acetate (MAM) i...
International audienceIn humans, cortical malformations are highly epileptogenic. In rats, prenatal ...
The administration of the antimitotic compound methylazoxymethanol (MAM) to gestating rats induces a...
The administration of methylazoxymethanol (MAM) to pregnant rats induced a marked reduction in the w...
Metabotropic glutamate receptors (mGluRs) have been implicated in a number of hippocampal functions ...
Malformations of neocortical development such as microgyria (MG) and periventricular nodular heterot...
Methylazoxymethanol acetate (MAM Ac) injected into pregnant rats at a dose of 25 mg/kg at gestationa...
We have generated an experimental ‘double-hit ’ model of chronic epilepsy to recapitulate the co-exi...
Administration of the DNA-alkylating agent methylazoxymethanol acetate (MAM) on embryonic day 17 (E1...